Skip to main content

Trevi Therapeutics, Inc.

corporate_fare Company Profile

Trevi Therapeutics, Inc.

TRVI·NASDAQ·Life Sciences·CIK 0001563880

The company is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio (oral nalbuphine ER). Haduvio is an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). This therapy is an oral extended-release formulation of nalbuphine. Haduvio works on the cough reflex by acting centrally and peripherally as a kappa receptor agonist and a mu receptor antagonist ("KAMA"), targeting opioid receptors involved in controlling chronic cough. Kappa- and mu-opioid receptors are known to be critical mediators of cough. Nalbuphine, in its injectable form, has been approved and marketed for pain indications for decades in the U.S. and Europe. Haduvio's mechanism of action also reduces the risk of abuse associated with mu-opioid agonists because it blocks the mu-opioid receptor. Parenteral nalbuphine is not classified as a controlled substance by the U.S. Drug Enforcement Agency and in most of Europe. The company is developing Haduvio for IPF-related chronic cough, a progressive fibrosing interstitial lung disease with high mortality rates. The median survival after an IPF diagnosis is 3 to 5 years. There are approximately 150,000 U.S. patients with IPF, and two-thirds of these patients experience uncontrolled chronic cough. Patients may cough up to 1,500 times per day. There are currently no FDA-approved therapies for IPF-related chronic cough.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for TRVI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for TRVI spans 8-K, 10-Q, DEF 14A, 424B5.

Recent high-impact activity:

  • Trevi Posts Wider Q3 Loss, $299.4M Cash Runway Into 2030, ILD Phase 2 Set for Q1 2027
  • Trevi Therapeutics Q2 2026: $318.9M Cash and Phase 3 IPF Cough Trial Underway
  • Stockholders Approve Doubling Authorized Shares and Expanding Stock Incentive Plan
  • Trevi Therapeutics Secures $162M in April Offering, Extends Cash Runway into 2030
  • Trevi Raises $162M, Extends Cash Runway to 2030, Accelerating Haduvio Phase 3 Trials

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$42.76M
Diluted EPS
-$0.32
Op. Cash Flow
-$42.09M
Free Cash Flow
-$42.1M
Operating Income
-$49.33M
Cash & Equivalents
$18.91M
Debt / Equity
0.00×
Shares Outstanding
128.31M sh
Source: 10-K · filed 2026-03-17 · accession 0001193125-26-110783

Short Interest & Short Volume

10.13 days to cover

FINRA reported short interest of 16,855,987 shares in TRVI as of the October 30, 2026 settlement, a 5.3% increase from the prior period — about 10.1 days to cover at its recent average daily volume. On November 20, 2026, 27.6% of TRVI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)16,855,987 shares as of October 30, 2026
Change vs prior period▲ 5.3%
Days to cover10.13 at avg daily volume of 1,663,689
Daily short volume (FINRA facilities)27.6% of 903,045 shares on November 20, 2026
5-day average short volume34.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with T →
$13.46 +0.82% today
52-week range · as of 2026-11-09 $9.82 – $20.22
Market cap
$1.9B
Volume
2.1M (1.1× avg)
3-mo avg 1.9M
Live data · 2026-11-22 12:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TRVI - Latest Insights

TRVI
Nov 09, 2026, 4:26 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.58
Real-time Price: $13.46 info
Change: -$2.12 (-14%) info
Market Cap: $1.903B info
TRVI
Aug 06, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.50
Real-time Price: $13.46 info
Change: -$5.04 (-27%) info
Market Cap: $1.903B info
TRVI
Jun 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.93
Real-time Price: $13.46 info
Change: -$0.470 (-3%) info
Market Cap: $1.903B info
TRVI
May 05, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $14.34
Real-time Price: $13.46 info
Change: -$0.880 (-6%) info
Market Cap: $1.903B info
TRVI
May 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $14.66
Real-time Price: $13.46 info
Change: -$1.20 (-8%) info
Market Cap: $1.903B info
TRVI
Apr 21, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $14.62
Real-time Price: $13.46 info
Change: -$1.16 (-8%) info
Market Cap: $1.903B info
TRVI
Apr 20, 2026, 4:18 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $15.10
Real-time Price: $13.46 info
Change: -$1.64 (-11%) info
Market Cap: $1.903B info
TRVI
Apr 17, 2026, 4:17 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $15.23
Real-time Price: $13.46 info
Change: -$1.77 (-12%) info
Market Cap: $1.903B info
TRVI
Apr 17, 2026, 8:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.60
Real-time Price: $13.46 info
Change: -$0.1365 (-1%) info
Market Cap: $1.903B info
TRVI
Apr 16, 2026, 10:42 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $13.49
Real-time Price: $13.46 info
Change: -$0.030 (-0.22%) info
Market Cap: $1.903B info
TRVI
Apr 16, 2026, 4:16 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $13.40
Real-time Price: $13.46 info
Change: +$0.060 (+0.45%) info
Market Cap: $1.903B info
TRVI
Apr 16, 2026, 4:10 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.70
Real-time Price: $13.46 info
Change: -$0.240 (-2%) info
Market Cap: $1.903B info
TRVI
Apr 10, 2026, 4:32 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $13.19
Real-time Price: $13.46 info
Change: +$0.270 (+2%) info
Market Cap: $1.903B info
TRVI
Mar 17, 2026, 4:08 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $10.88
Real-time Price: $13.46 info
Change: +$2.58 (+24%) info
Market Cap: $1.903B info
TRVI
Mar 17, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.10
Real-time Price: $13.46 info
Change: +$2.36 (+21%) info
Market Cap: $1.903B info
TRVI
Mar 17, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $10.88
Real-time Price: $13.46 info
Change: +$2.58 (+24%) info
Market Cap: $1.903B info
TRVI
Mar 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.12
Real-time Price: $13.46 info
Change: +$0.340 (+3%) info
Market Cap: $1.903B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets